
Broncus Holding Corporation
2216.HKHKSEHealthcareMedical - Devices
最新数据
HK$0.645
+HK$0.01 · +1.57%
2216.HK公司概览
盘中时间采用HKT。市场数据可能有所延迟。
公司概况
公司网站Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
- 行业
- Medical - Devices
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Hong Xu
- 上市以来
- 2021年9月24日
- 雇员
- 191
市场位置
52周区间
当前HK$0.645,
- 开盘价
- HK$0.645
- 前收盘价
- HK$0.635
- 成交量
- 20.25万
- 0.41× 平均值
- 平均成交量
- 49.85万
- 日均成交量
- 市值
- 3.4亿 HKD
- 贝塔
- 1.19
- 市场参考 1
- 50天平均值
- HK$0.6678
- 低于平均水平-3.41%
- 200天平均值
- HK$1.462
- 低于平均水平-55.88%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 1.16亿 USD
- 市盈率(TTM)
- -2.22×
- 市净率(TTM)
- 0.27×
- 市销率(TTM)
- 248.7×
- EV/EBITDA
- -5.11×
- 盈利收益率
- -12.09%
- 自由现金流收益率
- -6.79%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- -1585.06%
- 营业利润率
- -14017.85%
- 净利润率
- -10273.01%
- 净资产收益率
- -11.92%
- 资产收益率
- -11.45%
- 投入资本回报率
- -16.24%
财务健康
- 负债权益比
- 0×
- 流动比率
- 22.7×
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 17.4万 USD | 813.1万 USD | 1025.5万 USD | 941.3万 USD | 1089.1万 USD |
| 销货成本 | 109.1万 USD | 199.2万 USD | 302.8万 USD | 209.8万 USD | 214.9万 USD |
| 毛利 | −91.7万 USD | 613.9万 USD | 722.7万 USD | 731.5万 USD | 874.2万 USD |
| 研究与开发 | 777.2万 USD | 1147.1万 USD | 2015.4万 USD | 1916.7万 USD | 1675.9万 USD |
| 销售、一般及管理费用 | 1570.2万 USD | 1575.5万 USD | 2041.5万 USD | 2041.8万 USD | 3125.2万 USD |
| 营业费用 | 2347.4万 USD | 2862.7万 USD | 4044.8万 USD | 4002.3万 USD | 4617.1万 USD |
| 利息收入 | 549.01万 USD | 653.4万 USD | 604.1万 USD | 262.8万 USD | 16.1万 USD |
| 利息支出 | 4005.9 USD | 8.4万 USD | 16.3万 USD | 9.8万 USD | 17万 USD |
| 折旧和摊销 | 170.6万 USD | 212.2万 USD | 286.6万 USD | 213.1万 USD | 269.1万 USD |
| 营业利润 | −2439.1万 USD | −2248.8万 USD | −3322.1万 USD | −3270.8万 USD | −3985.3万 USD |
| 净利润 | −1787.5万 USD | −1530.3万 USD | −2809.1万 USD | −2803.6万 USD | −2.36亿 USD |
公司数据更新于 2026年8月24日。
财报历史与展望
- EPS超预期率
- 20%
- 超预期1次、低于预期2次、符合预期2次
- 平均EPS意外幅度
- -83.11%
- 5 类似报告
- 最新每股收益结果
- -0.16
EPS:实际值与预期值
近期已公布业绩
营收:实际值与预期值
近期已公布业绩
2216.HK同业公司
持有2216.HK的ETF
报告持有此股票敞口的交易所交易基金。
继续GoAI的研究
在 GoAI 中研究2216.HKresearch.disclaimer







